A New Category Is Forming in Medical Aesthetics. Independent Research Has Started Sizing It.

NEW YORK, Aug. 18, 2026 (GLOBE NEWSWIRE) -- Equity Insider News Commentary - For as long as aesthetic medicine has existed, its central promise has been to replace what time and gravity take away: fill a wrinkle, restore lost volume, reshape a contour. Now a shift in the underlying science is pointing toward something more ambitious. Instead of simply replacing volume, a growing body of research is asking whether the body's own tissue can be prompted to rebuild itself, and a new commercial category is beginning to form around that idea. At the center of the science is a structure most people have never heard of, the extracellular matrix, the framework that is essential for tissue restoration. One preclinical-stage company says it has spent more than a decade building on exactly that structure, before the category even had a name. Companies mentioned in today's commentary include: Conexeu Sciences Inc. (Nasdaq: CNXU), Eli Lilly and Company (NYSE: LLY), Novo Nordisk A/S (NYSE: NVO), AbbVie Inc. (NYSE: ABBV), and Bausch Health Companies Inc. (NYSE: BHC).